News
News - Lucas Meyer Cosmetics, a wholly owned subsidiary of Unipex Group, and leading company in the field of innovative active and functional ingredients for the cosmetics industry, announced that it has acquired Southern Cross Botanicals, the leading supplier of Australian botanical ingredients. This acquisition will expand the Lucas Meyer Cosmetics product line and is perfectly in line with its corporate vision, which focuses on innovation and client satisfaction.
News - Anges Québec is pleased with the new partnership concluded with the National Bank to support entrepreneurship and innovative Quebec companies. Under the three-year partnership, the two organizations will provide entrepreneurs with their combined expert advice to optimize the success of businesses supported by members of Anges Québec.
News - Recognizing the growing importance of Chinese outbound investment into Canada, this week the Consider Canada City Alliance Inc. is embarking on a three-city investment mission in the Asian country that the OECD predicts will be home to the world’s largest economy as soon as 2016.
News - Nemaska Lithium announced that they have begun the execution of their lithium hydroxide marketing strategy beginning in Asia where numerous battery cathode manufacturers are located. The Company's CEO, Guy Bourassa, and Technical Manager, Jean Francois Magnan, are in Asia this week to initiate discussions with key customers for supply of lithium hydroxide products. The two will begin the trip in Taiwan, then onto to Hong Kong and Mainland China. In addition, Mr. Bourassa has been invited as a featured speaker at the 5th World Cobalt and Lithium Forum held in Chengdu, China.
News - Asmacure, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, announced the start of a phase 1/2 clinical trial of its lead compound, ASM-024, in a dry powder for inhalation formulation. The company's lead product, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects and has demonstrated anti-inflammatory effects, bronchoprotection and smooth muscle relaxation in pre-clinical asthma models.
News - Aeterna Zentaris announced that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.
News - Frima Studio is diving headfirst into the children’s animation industry, announcing a new co-production agreement on the eve of MipTV in Cannes, France. In the wake of their recent agreement to co-produce the Squids series with Moonscoop, Frima continues expanding their animation footprint with an ambitious new project, Phoenix Park.
News - ISO (the International Organization for Standardization) 9001: 2008 specifies the requirements for a quality management system and the processes for continuous improvement and assurance of conformity to customer, regulatory and statutory applicable provisions. By this certification the company demonstrates its capacity to consistently provide products that meet customer requirements. This certification is in direct connection with the sustained implementation, in the recent years, of a culture of continuous improvement where each member of the company contributes daily to improve the customer experience while creating value for shareholders.
News - Aeterna Zentaris announces the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in endometrial cancer.
News - Aeterna Zentaris presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models. Results further showed the compounds' high potential for the treatment of luteinizing hormone-releasing hormone ("LHRH") receptor positive tumors. Data were presented earlier today by Babette Aicher, PhD, the Company's Director of Preclinical Development, during a poster presentation at the American Association for Cancer Research ("AACR") annual meeting currently being held in Washington D.C.
